Kontakt Adresse MorphoSys AG Semmelweisstr. Planegg Deutschland Phone: + - Fax: + - E-Mail: [email protected] MorphoSys US Inc.
It has a alexa rank of #1,312,940 in the world. It is a domain having .de extension. It is estimated worth of $ 960.00 and have a daily income of around $ 4.00. As no active threats were reported recently, morphosys.de is SAFE to browse.
Daily Unique Visitors: | 668 |
Daily Pageviews: | 1,336 |
Income Per Day: | $ 4.00 |
Estimated Worth: | $ 960.00 |
Google Indexed Pages: | Not Applicable |
Yahoo Indexed Pages: | Not Applicable |
Bing Indexed Pages: | 5,030 |
Google Backlinks: | Not Applicable |
Bing Backlinks: | 147,000 |
Alexa BackLinks: | Not Applicable |
Google Safe Browsing: | No Risk Issues |
Siteadvisor Rating: | Not Applicable |
WOT Trustworthiness: | Very Poor |
WOT Privacy: | Very Poor |
WOT Child Safety: | Very Poor |
Alexa Rank: | 1,312,940 |
PageSpeed Score: | 65 ON 100 |
Domain Authority: | 49 ON 100 |
Bounce Rate: | Not Applicable |
Time On Site: | Not Applicable |
Total Traffic: | No Data |
Direct Traffic: | No Data |
Referral Traffic: | No Data |
Search Traffic: | No Data |
Social Traffic: | No Data |
Mail Traffic: | No Data |
Display Traffic: | No Data |
MorphoSys veröffentlicht Ergebnisse für die ersten neun Monate und das...
MorphoSys mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer.
Jul 06, 2017 · MorphoSys is committed to developing exceptional new treatments for patients suffering from serious diseases. The biotechnology company was founded in summer of...
MorphoSys, Planegg. 286 likes. Our mission is to make exceptional innovative biopharmaceuticals to improve lives of patients suffering serious diseases.
MORPHOSYS Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as...
As of the 4th of December, MORPHOSYS secures the mean deviation of 1.85, and Risk Adjusted Performance of (0.10).In respect to fundamental indicators, the technical analysis...
Dr. Claudia Gutjahr-Löser Head of Corporate Communications & Investor Relations. Dr. Steffen Heeger Head of Clinical Development. Dr. Bernd Hutter Head of Intellectual Property
Lena-Christ-Str. 48 82152 Martinsried/Planegg Germany Phone:: +49-89-89927-0 Fax: +49-89-89927-222 Email: [email protected] www.morphosys.de. CORPORATE COMMUNICATIONS AND...
You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.
Dec 01, 2020 · DGAP-News: MorphoSys AG / Schlagwort(e): Sonstiges Thomas Biegi leitet die Unternehmenskommunikation bei MorphoSys 01.12.2020 / 22:02 Für …
Die MorphoSys AG ist ein 1992 gegründetes biopharmazeutisches Unternehmen mit Sitz in Planegg in der Nähe von München.Zur Gesellschaft gehört eine hundertprozentige...
We are very happy to announce that today MorphoSys and Incyte have entered into a collaboration and license agreement.. The partnership brings together MorphoSys’ strong...
* This phone number available for 3 min is not the recipient’s number but a number from a service which will put you through to that person. This service is produced by Kompass.
Year on year MorphoSys AG 's revenues fell -6.13% from 76.44m to 71.76m. This along with an increase in selling, general and administrative costs has contributed to a reduction...
Weitere Informationen unter www.morphosys.de. Monjuvi(R) und CyCAT(R) sind eingetragene Warenzeichen der MorphoSys AG. Tremfya(R) ist ein eingetragenes Warenzeichen von Janssen...
MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation...
Oct 01, 2020 · The org chart of Morphosys contains its 39 main executives including Jean-Paul Kress, Jens Holstein and Malte Peters.
Aktuelle Nachrichten & Diskussionen aus dem w:o Forum zu Morphosys | 663200. Seien Sie informiert.
Dec 02, 2020 · Weitere Informationen unter https://www.morphosys.de. Monjuvi (R) und HuCAL (R) sind eingetragene Warenzeichen der MorphoSys AG Tremfya (R) ist ein eingetragenes...
MorphoSys’s mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Innovative technologies and smart...
MORPHOSYS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie MorphoSys | 663200 | DE0006632003
About MorphoSys AG. MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and …
H1 Headings: | 1 | H2 Headings: | 1 |
H3 Headings: | Not Applicable | H4 Headings: | 3 |
H5 Headings: | Not Applicable | H6 Headings: | Not Applicable |
Total IFRAMEs: | Not Applicable | Total Images: | 4 |
Google Adsense: | Not Applicable | Google Analytics: | Not Applicable |
Words | Occurrences | Density | Possible Spam |
---|---|---|---|
Zur Mitteilung | 10 | 2.105 % | No |
Medien und | 4 | 0.842 % | No |
MorphoSys US | 3 | 0.632 % | No |
MorphoSys und | 3 | 0.632 % | No |
MorphoSys AG | 3 | 0.632 % | No |
und Incyte | 3 | 0.632 % | No |
49 89 | 2 | 0.421 % | No |
auf Twitter | 2 | 0.421 % | No |
89 899 | 2 | 0.421 % | No |
US Inc | 2 | 0.421 % | No |
und Investoren | 2 | 0.421 % | No |
Medien InformationenHauptmenü | 2 | 0.421 % | No |
Business Development | 2 | 0.421 % | No |
COVID19 auf | 2 | 0.421 % | No |
13012020 MorphoSys | 2 | 0.421 % | No |
Mitteilung 13012020 | 2 | 0.421 % | No |
für Tafasitamab | 2 | 0.421 % | No |
um so | 2 | 0.421 % | No |
Incyte unterzeichnen | 2 | 0.421 % | No |
unterzeichnen globalen | 2 | 0.421 % | No |
Words | Occurrences | Density | Possible Spam |
---|---|---|---|
innovative biopharmazeutische Medikamente zu | 2 | 0.421 % | No |
biopharmazeutische Medikamente zu entwickeln | 2 | 0.421 % | No |
und innovative biopharmazeutische Medikamente | 2 | 0.421 % | No |
herausragende und innovative biopharmazeutische | 2 | 0.421 % | No |
ist es herausragende und | 2 | 0.421 % | No |
es herausragende und innovative | 2 | 0.421 % | No |
Medikamente zu entwickeln um | 2 | 0.421 % | No |
zu entwickeln um so | 2 | 0.421 % | No |
das Leben schwerkranker Patienten | 2 | 0.421 % | No |
Leben schwerkranker Patienten zu | 2 | 0.421 % | No |
so das Leben schwerkranker | 2 | 0.421 % | No |
um so das Leben | 2 | 0.421 % | No |
entwickeln um so das | 2 | 0.421 % | No |
Mission ist es herausragende | 2 | 0.421 % | No |
Unsere Mission ist es | 2 | 0.421 % | No |
MorphoSys und Incyte unterzeichnen | 2 | 0.421 % | No |
und Incyte unterzeichnen globalen | 2 | 0.421 % | No |
Auswirkungen von COVID19 auf | 2 | 0.421 % | No |
von COVID19 auf den | 2 | 0.421 % | No |
Zur Mitteilung 13012020 MorphoSys | 2 | 0.421 % | No |
Host | IP Address | Country | |
---|---|---|---|
ns.udag.de | 192.174.68.8 | Austria | |
ns.udag.net | 176.97.158.8 | Austria | |
ns.udag.org | 176.97.158.91 | Austria |
Host | Type | TTL | Extra |
---|---|---|---|
morphosys.de | A | 589 |
IP: 188.40.105.138 |
morphosys.de | NS | 86400 |
Target: ns.udag.net |
morphosys.de | NS | 86400 |
Target: ns.udag.org |
morphosys.de | NS | 86400 |
Target: ns.udag.de |
morphosys.de | SOA | 600 |
MNAME: ns.udag.de RNAME: hostmaster.united-domains.de Serial: 2019102401 Refresh: 10800 Retry: 3600 Expire: 604800 |
morphosys.de | MX | 3600 |
Target: mx01.morphosys.com |
Scientific Minds is a publisher of technology-based science education products built from state standards. Our product development is based on research proving that students...
Voyageurs du Monde : agence de voyage spécialiste des voyages sur mesure. Consultez toutes nos offres de séjours à la carte, week-ends de charme, autotours, croisières de luxe…...